Teva up on strong 2024 3rd-qtr financial results

6 November 2024

Teva Pharmaceutical Industries’ (NYSE and TASE: TEVA) shares were up 4% at 7,323 shekels today reported results for the quarter ended September 30, 2024.

Teva’s third quarter earnings per share (EPS) of $0.69, $0.03 better than analyst’s estimate of $0.66. Revenue for the quarter came in at $4.33 billion, up 13% and higher than the consensus estimate of $4.14 billion.

On a non-generally accepted accounting principles (GAAP) basis, gross profit was $2,327 million, an increase of 13% compared to $2,060 million in the third quarter of 2023

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics